VP-002 / Cycle Group - LARVOL DELTA

CRISTAL-APC - A multi-center, open label Phase I/II study of VP-002, a C-C motif chemokine receptor 1 (CCR1) inhibitor,in combination with nab-paclitaxel and gemcitabine (nPG) inpatients withpancreatic ductal adenocarcinoma (PDAC) (AACR-NCI-EORTC 2025) - "Exploratory endpoints to evaluate pharmacodynamic effects or biomarkers predictive of radiological or pathological response from CCR1 inhibition as monotherapy or in combination with chemotherapy include biomarker analysis of infiltrating immune cells using CODEX, genomic sequencing, circulating chemokine profiles, spatial transcriptomic profile and dietary impacts on pharmacokinetics. CRISTAL-APC (Clinical Trial Registry Number: ISRCTN16463547) opened in April 2025 with two patients enrolled into the Phase I escalation as of June 2025."

Clinical • Combination therapy • P1/2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma